The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on TNXP: Tonix Pharma Announces Promising Phase 1 Trial Results Tonix Pharmaceuticals announces results from Phase 1 trial for TNX-1500 Tonix Pharmaceuticals trading halted, news pending Tonix Pharma Promotes Fogarty to Chief Technology Officer Tonix Pharmaceuticals promotes Fogarty to CTO Disclaimer & DisclosureReport an Issue